注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Altimmune Inc是一家臨床階段的生物製藥公司,專注於開發肥胖症和肝病的治療方法。該公司的主要候選產品pemvidutide(INN,原名ALT-801)是一種GLP-1/胰高血糖素雙受體激動劑,正在開發用於治療肥胖和非酒精性脂肪性肝炎(NASH)。該公司還正在開發HepTcell,這是一種免疫治療劑,旨在實現慢性乙型肝炎的功能性治療。該公司已經啟動了HepTcell的II期臨床試驗,並在II期和I期臨床開發中使用培維多肽治療多種適應症。它正在美國、英國、加拿大、德國和西班牙進行HepTcell的II期臨床試驗,並在澳大利亞進行培維多肽I期臨床試驗。其全資子公司包括Altimmune,LLC、Altimmune UK,Limited、Spitfire Pharma,LLC和Altimmune AU Pty,Limited。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Wayne F. Pisano | 66 | 2018 | Independent Director |
David J. Drutz | 82 | 2011 | Independent Director |
Mitchel B. Sayare | 73 | 2010 | Independent Chairman |
Philip L. Hodges | 52 | 2017 | Independent Director |
Vipin K. Garg | 63 | 2018 | President, CEO & Director |
Klaus O. Schafer | 74 | 2017 | Independent Director |
Diane Kathryn Jorkasky | 72 | 2020 | Independent Director |
John M. Gill | 72 | 2004 | Independent Director |
Caroline M. Apovian | - | 2022 | Member of Obesity Scientific Advisory Board |
Louis J. Aronne | 68 | 2022 | Member of Obesity Scientific Advisory Board |
Robert F. Kushner | - | 2022 | Member of Obesity Scientific Advisory Board |
Donna Ryan | - | 2022 | Member of Obesity Scientific Advisory Board |
Juan Pablo Frias | - | 2022 | Member of Obesity Scientific Advisory Board |
Daniel Joshua Drucker | - | 2022 | Member of Obesity Scientific Advisory Board |
Samuel Klein | - | 2022 | Member of Obesity Scientific Advisory Board |
Catherine Angell Sohn | 71 | 2023 | Independent Director |
Lee M. Kaplan | - | 2023 | Member of Obesity Scientific Advisory Board |
Rohit Loomba | - | 2022 | Member of Mash Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核